{"id":78169,"date":"2023-07-04T04:45:40","date_gmt":"2023-07-04T04:45:40","guid":{"rendered":"https:\/\/dailytalks.org\/?p=78169"},"modified":"2023-07-04T04:45:40","modified_gmt":"2023-07-04T04:45:40","slug":"bayer-to-acquire-exclusive-license-from-cedilla-therapeutics-on-selective-inhibitors-in-pre-clinical-precision-oncology","status":"publish","type":"post","link":"https:\/\/dailytalks.org\/?p=78169","title":{"rendered":"Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology"},"content":{"rendered":"<p>Berlin, Germany and Boston, US, June 1, 2023 \u2013 Bayer and Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today announced an exclusive license agreement to develop and commercialize Cedilla Therapeutics\u2019 CyclinE1\/CDK2 complex inhibitors which selectively address oncogenic drivers.Overexpression or genetic activation of Cyclin Dependent Kinase 2 (CDK2) binding partner cyclin E is a key oncogenic process in several cancers&#8230;<br \/><a href=\"https:\/\/www.bayer.com\/media\/en-us\/bayer-to-acquire-exclusive-license-from-cedilla-therapeutics-on-selective-inhibitors-in-pre-clinical-precision-oncology\/\" class=\"button purchase\" rel=\"nofollow noopener\" target=\"_blank\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Berlin, Germany and Boston, US, June 1, 2023 \u2013 Bayer and Cedilla Therapeutics, a biotechnology<\/p>\n","protected":false},"author":1,"featured_media":78170,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35],"tags":[],"class_list":["post-78169","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tech"],"featured_image_urls":{"full":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/07\/78169-bayer-to-acquire-exclusive-license-from-cedilla-therapeutics-on-selective-inhibitors-in-pre-clinical-precision-oncology.jpg",1200,630,false],"thumbnail":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/07\/78169-bayer-to-acquire-exclusive-license-from-cedilla-therapeutics-on-selective-inhibitors-in-pre-clinical-precision-oncology-150x150.jpg",150,150,true],"medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/07\/78169-bayer-to-acquire-exclusive-license-from-cedilla-therapeutics-on-selective-inhibitors-in-pre-clinical-precision-oncology-300x158.jpg",300,158,true],"medium_large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/07\/78169-bayer-to-acquire-exclusive-license-from-cedilla-therapeutics-on-selective-inhibitors-in-pre-clinical-precision-oncology-768x403.jpg",640,336,true],"large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/07\/78169-bayer-to-acquire-exclusive-license-from-cedilla-therapeutics-on-selective-inhibitors-in-pre-clinical-precision-oncology-1024x538.jpg",640,336,true],"1536x1536":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/07\/78169-bayer-to-acquire-exclusive-license-from-cedilla-therapeutics-on-selective-inhibitors-in-pre-clinical-precision-oncology.jpg",1200,630,false],"2048x2048":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/07\/78169-bayer-to-acquire-exclusive-license-from-cedilla-therapeutics-on-selective-inhibitors-in-pre-clinical-precision-oncology.jpg",1200,630,false],"chromenews-featured":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/07\/78169-bayer-to-acquire-exclusive-license-from-cedilla-therapeutics-on-selective-inhibitors-in-pre-clinical-precision-oncology-1024x538.jpg",1024,538,true],"chromenews-large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/07\/78169-bayer-to-acquire-exclusive-license-from-cedilla-therapeutics-on-selective-inhibitors-in-pre-clinical-precision-oncology-825x575.jpg",825,575,true],"chromenews-medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/07\/78169-bayer-to-acquire-exclusive-license-from-cedilla-therapeutics-on-selective-inhibitors-in-pre-clinical-precision-oncology-590x410.jpg",590,410,true]},"author_info":{"display_name":"Jonathan Jeriah","author_link":"https:\/\/dailytalks.org\/?author=1"},"category_info":"<a href=\"https:\/\/dailytalks.org\/?cat=35\" rel=\"category\">Tech<\/a>","tag_info":"Tech","comment_count":"0","_links":{"self":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/78169","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=78169"}],"version-history":[{"count":0,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/78169\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/media\/78170"}],"wp:attachment":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=78169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=78169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=78169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}